BridgeBio's US sales share fell from 90% to 72% in a year
Sales are concentrated in the United States: 72% of this quarter's $353.17 M, down from 90% a year earlier. The filing gives regions only as percentages, so the dollar figures on this page are estimates, each share times total sales. Only the percentages are reported; the dollars are our arithmetic on them. That matters because the EMEA slice rose from $9.29 M to $97.48 M, the fastest riser on the page. The filing does not give the regional dollar amounts.
Why did Europe, the Middle East and Africa jump? Its share went from 7.7% to 27.6% of sales, and the filing says revenue is attributed to regions by where customers or license partners are located. The quarter's $75.0 M sales milestone sits in the license line, which the filing ties to a Bayer agreement. If that milestone is attributed to a partner in the EMEA region, it would account for most of the $88.18 M rise there. The filing does not say where it was booked.
What it means: the regional story is thinner than the headline suggests. APAC slipped from $3.26 M to $2.47 M, down 24%, while the United States lost share. What would settle it is a regional table that shows where the milestone was booked and whether the percentages match the dollars. Until then, the regional dollars stay an estimate built on rounded shares, and the milestone's place in that picture stays unproven. Will the next filing break out the milestone by region?

